HOME >> MEDICINE >> NEWS
Actonel reduced nonveterbral fracture as early as 6 months

g daily, the overall incidence of adverse events with the two dosing regimens was similar. The most commonly reported adverse events regardless of causality were infection (Actonel 35 mg 20.6 percent vs. Actonel 5 mg 19.0 percent), arthralgia (14.2 percent vs. 11.5 percent) and constipation (12.2 percent vs. 12.5 percent).

About The Alliance for Better Bone Health
The Alliance for Better Bone Health was formed by Procter & Gamble and Aventis Pharma in May 1997 to develop and market Actonel collaboratively in Europe, the United States and Canada. The Alliance promotes bone health and disease awareness through numerous activities to support physicians and patients around the globe.

About Procter & Gamble Pharmaceuticals
Procter & Gamble Pharmaceuticals is a part of Procter & Gamble Health Care, a division of The Procter & Gamble Company (NYSE:PG) a $40 billion global leader in the development, manufacturing and marketing of a broad range of consumer goods. In prescription drugs, P&G is focusing in the areas of endocrinology, cardiovascular and musculoskeletal diseases, as well as anti-infective therapies. Some of P&G's leading prescription products include Actonel (risedronate sodium tablets), Didronel? (etidronate disodium), Asacol? (mesalamine) and Macrobid? (nitrofurantoin monohydrate macrocrystals).


'"/>

Contact: Brian Devenny
bdevenny@hillandknowlton.com
212-885-0315
Hill and Knowlton
21-Jun-2002


Page: 1 2 3

Related medicine news :

1. Actonel helped preserve bone quality at five years, new data show
2. New analysis shows early intervention with Actonel reduces first vertebral fracture risk
3. FDA approves Actonel for once-a-week use
4. Study shows Actonel reduces vertebral fracture risk 70 percent in patients on chronic steroid therapy
5. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
6. Hypothyroidism associated with reduced breast cancer risk
7. Cocaine addicts show reduced brain structure that underlies judgment
8. Breast cancer risk, prognosis and weight gain reduced with physical activity
9. New analysis links breastfeeding to reduced risk of childhood leukemia
10. Teenage hormone therapy to reduce adult height of tall girls linked to reduced fertility
11. Biopharmaceutical manufacturing efficiencies signal reduced healthcare costs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... Md. (PRWEB) , ... February 19, 2019 , ... ... Alan Einhorn, both of counsels to Foley & Lardner LLP, as Recognized Consultants. ... and digital health companies, interested in pursuing CHQI accreditation. , Ms. Wein ...
(Date:2/19/2019)... ... 19, 2019 , ... Reproductive Biology Associates (RBA), ... and a part of the Prelude Fertility (Prelude) network, announces today ... Hospital. , The only reproductive endocrinology practice on the Piedmont Atlanta hospital campus, ...
(Date:2/19/2019)... ... February 18, 2019 , ... ... U.S. Patent No. 10,195,147 titled, “Dry powder aspirin compositions with magnesium stearate,” protect ... also protected by three previously granted utility patents, two issued by the USPTO ...
(Date:2/19/2019)... ... February 19, 2019 , ... K.J. Kidd, a Missouri native born ... a Missed Opportunity”: an autobiographical work offered to encourage other women to be proactive ... , Kidd shares, “On September 28th of 2013, I spent my entire morning walking ...
(Date:2/19/2019)... ... , ... Diploid , leading AI-based software provider for rare disease diagnostics, ... into a partnership to improve genome interpretation for rare disease diagnostics. , With its ... Moon allows its users to go from VCF to causal variant in just minutes ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... ... February 19, 2019 , ... ... Senior Vice President. Kunney, based in Atlanta, is an experienced IT leader ... that effectively integrate within the clinical setting. He works with hospitals, health ...
(Date:2/19/2019)... SEATTLE (PRWEB) , ... February 19, 2019 , ... ... device company developing non-invasive treatments for cancers and other serious diseases, today announced ... early feasibility study in CNS Oncology suggesting that the Nativis Voyager device is ...
(Date:2/19/2019)... GREENVILLE, S.C. (PRWEB) , ... February 19, 2019 , ... ... North America for the scientific development, healthcare training and clinical application of medical infrared ... take place on September 7-8 at the Emory University Conference Center in Atlanta, GA. ...
Breaking Medicine Technology:
Cached News: